beta-hydroxyisovalerylshikonin has been researched along with imatinib mesylate in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Asaka, M; Hirabayashi, T; Hori, K; Kajimoto, S; Kondo, T; Masuda, Y; Nakajo, S; Nakaya, K; Nishida, A | 1 |
| Miyasaka, T; Nakaya, K | 1 |
1 review(s) available for beta-hydroxyisovalerylshikonin and imatinib mesylate
| Article | Year |
|---|---|
A shikonin derivative, beta-hydroxyisovalerylshikonin, is an ATP-non-competitive inhibitor of protein tyrosine kinases.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Apoptosis; Benzamides; Drug Interactions; Humans; Imatinib Mesylate; K562 Cells; Naphthoquinones; Phosphorylation; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Structure-Activity Relationship | 2003 |
1 other study(ies) available for beta-hydroxyisovalerylshikonin and imatinib mesylate
| Article | Year |
|---|---|
Beta-hydroxyisovalerylshikonin induces apoptosis in human leukemia cells by inhibiting the activity of a polo-like kinase 1 (PLK1).
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Benzamides; Cell Cycle Proteins; Cell Line; Cysteine Proteinase Inhibitors; DNA, Complementary; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Genistein; HL-60 Cells; Humans; Imatinib Mesylate; K562 Cells; Kidney; Leukemia, Myeloid; Naphthoquinones; Neoplasm Proteins; Oligodeoxyribonucleotides, Antisense; Oligonucleotide Array Sequence Analysis; Phosphorylation; Piperazines; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Kinases; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; U937 Cells | 2003 |